We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Metabolomics Analysis Method Used for Diagnosis of IBD

By LabMedica International staff writers
Posted on 15 Jul 2019
A team of Canadian researchers used an advanced metabolomics approach to differentiate inflammatory bowel syndrome (IBS) from other related gastrointestinal disorders.

Irritable bowel syndrome (IBS), the most commonly diagnosed functional gastrointestinal (GI) disorder in developed countries, is characterized by chronic abdominal pain and altered bowel habits. More...
Accurate and timely diagnosis of IBS is challenging as it relies on observation of symptoms and an evolving set of exclusion criteria to distinguish it from other related GI disorders such as inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis.

To develop better a better method for diagnosis of IBS, investigators at McMaster University (Montreal, Canada) used multisegment injection-capillary electrophoresis-mass spectrometry to generate metabolite profiles in repeat urine specimens collected from a cohort of 42 IBS patients and compared them to profiles from 20 healthy controls.

Results revealed ten consistently elevated urinary metabolites in repeat samples collected from IBS patients at two different time points, which were associated with greater collagen degradation and intestinal mucosal turn-over processes likely due to low-grade inflammation. IBS-specific metabolites identified in urine included a series of hydroxylysine metabolites (O-glycosylgalactosyl-hydroxylysine, O-galactosyl-hydroxylysine, lysine), mannopyranosy-l-tryptophan, imidazole propionate, glutamine, serine, ornithine, dimethylglycine, and dimethylguanosine.

While the metabolomics approach avoided invasive blood sampling, colonoscopy, and/or tissue biopsies, the investigators warned that at this time its usefulness was limited somewhat by the propensity of IBS patients to suffer from additional illnesses, including depression, and that they took more prescribed medications than did the healthy controls.

“Diagnostic testing for IBS involves a long process of excluding other related gut disorders, such as inflammatory bowel disease,” said senior author Dr. Philip Britz-McKibbin, professor of chemistry and chemical biology at McMaster University.

"We were interested in finding if there is a better way to detect and monitor IBS that avoids invasive colonoscopy procedures while also giving us better insights into its underlying mechanisms.”

The study was published in the May 20, 2019, online edition of the journal Metabolomics.

Related Links:
McMaster University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.